PRG.L Regulatory News (PRG)

7 Jun 2006 08:18

Premier Research Group07 June 2006 7 June 2006 PREMIER RESEARCH GROUP ISSUE OF EQUITY Premier Research Group plc (AIM: PRG) ("Premier Research", "Company" or"Group"), the international pharmaceutical services group today announces that2,201,816 new ordinary shares of 1p each (the "New Ordinary Shares") have beenissued and allotted to the vendors of PharmData ("Vendors") pursuant to theacquisition agreement, as announced on 19 July 2005, and the achievement ofcertain performance milestones in the remainder of that calendar year.Subsequent to this issue, 2,139,089 of the New Ordinary Shares have been placedon behalf of the Vendors with institutional investors. Application has been made for the New Ordinary Shares, which will rank paripassu with existing ordinary shares, to be admitted to trading on AIM, andadmission is expected to take place at 8 a.m. on 12 June 2006. Premier Research Group plc Dr Simon Yaxley, Chief Executive Tel: 01344458311Bernard Gallagher, Chief Financial Officer Tel: 01344458309 Buchanan Communications Tel: 020 74665000Lisa Baderoon / Rebecca Skye Dietrich email:lisab@buchanan.uk.com Evolution SecuritiesSimon Leathers / Lloyd Thomas Tel: 020 7071 4300 Notes to editors: About Premier Research Premier Research is a growing contract research organisation (CRO) involved inthe design and execution of clinical trials (Phases II-IV) on behalf ofpharmaceutical and biotechnology companies. Premier is established in threetherapeutic areas - oncology, CNS (central nervous system) and anti-infectives -with a strong underlying expertise in paediatrics. Through a focused approach toclinical management, the company has built a reputation with its customers fordelivery of its services, and has demonstrated organic growth following itsrecent acquisitions. Premier has also established itself as an activeparticipant in the consolidation activity within the sector. This information is provided by RNS The company news service from the London Stock Exchange